First pig heart transplant recipient dies of heart failure, not rejection

Bennett, 57, and suffering from terminal heart disease received the heart in January this year from biotechnology company Revivcor, which produces genetically modified pigs.

The organ transplant showed for the first time that a genetically modified animal heart could function like a human heart without immediate rejection by the body, doctors said after a rare and successful surgery. But his death two months later raised questions about the procedure.

Earlier researchers pointed to a porcine virus – a preventable infection associated with devastating effects on transplants – as a possible cause of his death.

Now researchers say the transplanted pig’s heart worked well for several weeks and did not exhibit any specific signs of rejection by the patient’s body, even if it was carefully examined during an autopsy. Surgeons concluded that the patient died of cardiac arrest that was likely caused by a complex array of factors.

“Our findings at autopsy did not show evidence of rejection. Instead, we observed that the thickening and subsequent hardening of the heart muscle lead to diastolic heart failure, which means that the heart muscle is at rest and the heart is at rest. was not able to fill with blood as it is supposed to,” says Bartley Griffith, MD, professor at the university’s School of Medicine.

The team explained several factors that may have contributed to the development of heart failure, including the use of intravenous immunoglobulin, IVIG, a drug that is administered to the patient twice during the second month after transplant to prevent rejection and infection. was given to help.

The drug contains antibodies against pig cells that can interact with the pig’s heart, causing a reaction that damages the heart muscle. Evidence of DNA from a latent pig virus called porcine cytomegalovirus (PCMV) was also found through highly sensitive testing in the heart, which was first detected several weeks after surgery and later confirmed during organ autopsies. .

“We consider this to be an important learning experience. Knowing what we know now, we will change some of our practices and techniques in the future,” said Muhammad M. Mohiuddin, professor of surgery at the university.

The new discovery comes amid the US Food and Drug Administration (FDA) considering approving human clinical trials for pig-to-human organ transplantation.

The high-profile transplant has “raised public awareness of the field” and “made it an optimal time for public conversation” and clinical trials, FDA’s Office of Tissue and Advanced Medicine in Silver Spring, Maryland. Wilson Bryan, director of the recent US FDA advisory meeting.

Disclaimer: This story is auto-aggregated by a computer program and is not created or edited by FreshersLIVE.Publisher : IANS-media

Leave a Reply

Your email address will not be published.